| 49 | 1 | 11 |
| 下载次数 | 被引频次 | 阅读次数 |
目的:测定吉非罗齐的体内过程,作出相对生物利用度评价,为临床合理用药提供依据.方法:8名健康受试者交叉口服单剂量古非罗齐片和胶囊后,用HPLC法测定不同时间的血药浓度,经MCPKP软件拟合处理,并计算药物动力学参数.结果:吉非罗齐片和胶囊均符合开放一室模型,Tmax,Cmax,AUC0～∞分别为(1.61±0.49)和(1.66±0.47)h,(37.28±9.71)和(29.97±5.58)μg/ml;(128.48±24.36)和(119.55±19.48)μg/(h·ml).结论:吉非罗齐片剂对胶囊剂的相对生物利用度为107.26%.
Abstract：AIM:To study pharmacokinetics and bioavailability of gemfibrozil in 8 young healthy volunteers. METHODS: Acoording to the cross - over design,each volunteer was o-rally given gemfibrozil tablets and capsule in single dosage respectively,and the plasma concentrations in different time were determined by reversed-phase high-performance liquid method. RESULTS :The data were fitted by MCPKP program. The pharmacokinetics of gemfibrozil tablets and capsule could be described by open single compartment model. The Tmax, Cmax and AUCo~∞ of two products were (1. 61±0. 49)and (1. 66±0. 47)h,(37. 28±9. 71)and (29. 97±5. 58μg/ml;(28. 48±24. 36)and (119. 55±19. 48>μg/(h · ml) respectively. CONCLUSION: The relative bioavailiability of gemfibrozil talbets were 107-26% compared with capsule.
[1]Todd PA, Ward A. Gemfibrozil: a review of its pharmacodynamic and pharmacokinetic properties,and therapeutic use in dyslipidaemia. Drugs 1988, 36: 34
[2]Forland SC, Feng Y, Cutler RE. Apparent reduced absorption of gemfibrozil when given with colestipol. J Clin Pharmacol 1990, 30: 29
[3]Evans. JR, Forland SC, Cutler RE. The effect of renal function on the pharmacokinetics of gemfibrozil. Journal of Clinical Pharmacology 1987, 27:994
基本信息:
DOI：10.19577/j.cnki.issn10074406.1998.01.004
中图分类号:R96
引用信息:
[1]吴琳华,孙考祥,胡君茹,樊宏伟,孙绍福,陶志光,何彦文.吉非罗齐片和胶囊在健康人体内药物动力学和相对生物利用度比较[J].中国临床药学杂志,1998(01):12-15.DOI:10.19577/j.cnki.issn10074406.1998.01.004.
1998-02-15
1998-02-15